Quality of Life in a Randomized Trial Comparing Two Neoadjuvant Regimens for Locally Advanced Rectal Cancer – INCAGI004.

Rodrigo Otavio de Castro Araujo (.raraujooncologia@gmail.com)
INCA: Instituto Nacional de Cancer
https://orcid.org/0000-0002-0033-2545

Fernando Meton Vieira
Instituto COI

Ana Paula Victorino Ornellas
Instituto COI

Claudia Carrada Torres
INCA: Instituto Nacional de Cancer

Ivanir Martins
INCA: Instituto Nacional de Cancer

Simone Guaraldi
INCA: Instituto Nacional de Cancer

Marcus Vinicuis Valadão
INCA: Instituto Nacional de Cancer

Eduardo Linhares
INCA: Instituto Nacional de Cancer

Carlos Gil Ferreira
Oncoclinicas Institute for Research and Education

Luiz Claudio Thuler
INCA: Instituto Nacional de Cancer

Research Article

Keywords: Rectal Cancer, Quality of Life, Neoadjuvant Treatment, Radiotherapy, Chemotherapy, Surgical Oncology

Posted Date: November 15th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-121936/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Neoadjuvant chemoradiotherapy (neoCRT) followed by surgery is the standard of care for locally advanced rectal cancer (LARC), but the emergence of different drug regimens may result in different response rates. Good clinical response translates into greater sphincter preservation, but quality of life (QOL) may be impaired after treatment due to chemoradiotherapy and surgical side effects.

Objective: To prospectively evaluate the QOL in a randomized trial comparing two neoadjuvant regimens for locally advanced rectal cancer.

Methods: Stage II and III rectal cancer patients were randomized to receive neoCRT with either capecitabine (Group 1) or 5-Fu and leucovorin (Group 2) concomitant to long course radiotherapy. Clinical downstaging was accessed using MRI 6-8 weeks after treatment. EORTCs QLQ C30 and CR38 were applied before treatment (T0), after neoCRT (T1), after rectal resection (T2), early after adjuvant chemotherapy (T3), and one year after end of treatment or stoma closure (T4). Wexner scale was used for continence evaluation at T4. A C30SummaryScore (Geisinger et cols) was calculated to compare QOL results.

Results: 32 patients were assigned to Group 1 and 31 to Group 2. Clinical downstaging occurred in 70.0% of Group 1 and 53.3% of Group 2 (p=0.288). pCR was 23.3% in group 1 and 10.0% in Group 2(p=0.165). Sphincter preservation was 83.3% in Group 1 and 80.0% in Group 2(p=0.111). No difference in QOL was detected comparing the two treatment groups before and after neoCRT. C30SummaryScore detected improvement comparing T0 to T1 and deterioration comparing T1 to T2 (p=0.025), and global health status improved at T1 and T4 compared to T0(p=0.004). Mean Wexner scale score was 9.2, and a high score correlated with symptoms of diarrhea and defecation problems at T4.

Conclusions: Clinical and pathological response rates were equivalent in both treatment groups. QOL was improved after neoCRT corresponding to clinical response but decreased following rectal resection. Wexner score was high after sphincter preservation. C30SummaryScore was a useful tool to detect differences in overall QOL in EORTCs multiple item questionnaire.

Trial registration: NCT03428529. Registered 02/09/2018 - Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT03428529.

Background

Colorectal cancer is the third most common malignant neoplasia worldwide (1.4 million new cases/year)(1). In Brazil is the third most frequent cancer in men and second in woman(2). Locally advanced rectal cancer (LARC) is the denomination for tumors centered below the peritoneal reflection, usually <10-12 cm from the anal verge (AV), and that have extended beyond the muscularis propria or the rectum (AJCC clinical stage II and III)(3). Neoadjuvant chemo radiotherapy (neoCRT) using 5-fluorouracil and leucovorin (5-Fu/Lv) followed by total mesorectal excision (TME) is considered the standard of care for locally advanced rectal cancer (LARC) resulting in >70% 5-year survival(4, 5). Capecitabine is an oral substitute to 5-Fu that has been tested in neoadjuvant phase 2 trials that demonstrated superiority in clinical and pathological
response rates (6, 7) and phase 3 trials showing comparable efficacy(5, 8, 9). It has the potential advantages of synergism with radiation due to thymidine phosphorylase upregulation(10), increased concentration in colorectal tumor tissue (11) and the convenience of oral administration(12).

The adoption of total mesorectal excision (TME)(13) combined to the neoadjuvant treatment has resulted in excellent local control, with local recurrences occurring in 3-6% of patients (5, 14). Therefore, abdominoperineal resection or Miles’s operation (15) has been avoided progressively in favor of sphincter preserving procedures as low anterior resection and intersphincteric resection(16) when sufficient distal and circumferential negative margins are secured.

Besides advances in local control and sphincter preservation for LARC, quality of life (QOL) becomes a great problem after treatment due to temporary or permanent stoma creation (17), sexual and urinary dysfunction(18) and a myriad of defecation disfunctions now classified as low anterior resection syndrome (LARS)(19).

The European Organization for Research and Treatment on Cancer (EORTC) has published in 1993 a questionnaire with 30 questions, the QLQ C30(20), and has been extensively used to measure patient reported outcomes in oncology for all cancer types. It displays the QOL results in 15 domains divided in five functional scales, nine symptom scales and one global QOL scale. In rectal cancer it is usually applied with the addition of specific colorectal modules (21)(22). Nonetheless, QOL analysis using the multi-item scales may lead to conflicting conclusions because some symptoms may ameliorate after treatment whilst other may get worse. For example, some studies favor sphincter preservation (23) while others suggest equivalent or worse results comparing patients with low rectal anastomosis to definitive stoma (24).

A summary measure to aggregate the multi-dimensional QoL profile and to detect changes in overall QOL over time is particularly important in clinical trials, which are designed to pre-specified endpoints. The original two-item global QOL scale may not be comprehensive enough to detect changes between patient groups and/or changes over time. It has been shown that Global QOL scale could not detect deteriorating QOL in patients with progressive and terminal disease (25).

In this scenario a group of authors recently proposed a higher order summary score that performed well in an empirical model fit (26). It was calculated by the mean of all C30 scales except for financial problems scale and global QOL scale. This so denominated C30SumScore has been tested in a non-small cell Lung cancer study including 326 patients three months after lung resection and demonstrated better sensitivity to detect postoperative changes compared to the global QOL score(27). In addition, the C30SumScore was demonstrated to perform better than the global QOL scale and the physical functioning scale in predicting all-cause mortality in colon and rectal cancer patients(28).

In the present study we performed a QOL evaluation in LARC patients using EORTC’s QOL questionnaires and the new summary score to detect differences associated to the clinical response and to the surgical therapy in a randomized prospective trial comparing two different neoCRT regimens in a Brazilian cancer reference hospital.
Objective

To prospectively evaluate the impact of clinical response and surgical resection on QOL in a randomized trial comparing two different neoCRT regimens.

Methods

Study Design

This was a longitudinal prospective study approved by Ethics Committee of National Cancer Institute of Brazil (INCA) in 2010 under register number 83/10 (NCT03428529). Patients were randomized to receive neoCRT using either capecitabine or bolus 5-Fu/Lv concomitant to 50,4 Gy radiation on the rectum and adjacent lymph nodes. Figure 1 illustrates the study design. Clinical downstaging was the study primary endpoint and was defined as stage regression 6-8 weeks after neoCRT, using AJCC 7th edition(29).

Eligibility criteria

All eligible consecutive patients from 18 to 80 years with ECOG performance status 0-1 admitted in this single tertiary cancer hospital with rectal adenocarcinoma stage II and III that voluntarily agreed to participate were selected for inclusion. Distance from anal verge (AV) should not exceed 10 cm measured with rigid proctoscopy. Patients were staged before neoCRT and re-staged 6-8 weeks after it with thorax and abdominal computer tomography (CT), endorectal ultrasonography (EUS) and pelvic Magnetic Resonance Imaging (MRI). Patients were excluded if distant metastasis were found on pre-treatment staging, in case of serious comorbidities, pregnancy, or previous oncological treatment.

Neoadjuvant treatment

Eligible patients were randomized to receive one of the following regimens: oral capecitabine 1650mg/m² in two daily divided doses from Monday to Friday for five weeks (Group 1) intravenous bolus 5-Fu (350mg/m²) plus Leucovorin (20 mg/m²) days 1 to 5 and 29 to 33 (Group 2). Both schemes were concomitant to external beam three-dimension radiotherapy (50.4 Gy in 28 fractions).

Surgical Treatment

Surgical resection consisted of low anterior resection (LAR), intersphincteric resection (ISR) or abdominoperineal resection (APR), according to sphincter invasion using MRI classification of sphincter invasion after neoCRT(16) and it was planned 6-8 weeks after neoCRT completion. Patients without sphincter complex invasion were submitted to LAR; patients with internal sphincter invasion were candidates to ISR if >1mm was predicted; and APR was reserved for patients with external sphincter invasion or intersphincteric plane invasion after neoCRT. Diverting stomas were performed after low colorectal or coloanal anastomosis, and stoma closure was undertaken after the adjuvant chemotherapy completion.

Adjuvant treatment
Adjuvant chemotherapy was defined by pathological response. Patients with ypT0-2/N0 tumors received bolus 5-Fu 370mg/m² and Leucovorin 50mg/m² weekly for 30 consecutive weeks. Patients with ypT3-4 and/or ypN1 tumors received Oxaliplatin 85 mg/m² on days 1, 15 and 29 of each cycle, and bolus 5-Fu 500 mg/m² plus Leucovorin 20 mg/m² on days 1, 8, 15, 22, 29 and 36 of each cycle. Each cycle consisted of 6 weeks of chemotherapy followed by 2 weeks of rest, totaling 3 cycles, for a total of 24 weeks. Dose reduction, delay and discontinuation of treatment have followed the Common Terminology for Adverse Events (CTCAE) version 3.0 guideline.

Follow-up

Patients were followed by medical consultations every three months in the first two years and every six months in the three subsequent years until the completion of five years of follow-up, disease progression or death. CT scans and rectal endoscopy were performed every 6 months for detecting recurrences.

Quality of Life Evaluation

EORTC QLQ C30(20) and CR38(21) were applied at five different treatment moments: before neoCRT (T0), 6-8 weeks after neoCRT (T1), 30 days after surgery (T2), after adjuvant chemotherapy (T3), and one year after the end of the treatment or stoma closure (T4) (Figure 2). QLQ-C30 grouped in nine multiple item scales and six single item scales and has been tested and validated in the Brazilian population (30). The multiple item scales comprise five functional scales (physical, cognitive, emotional, social, and role functioning), and three symptom scales (fatigue, pain, and nausea/vomiting), a global health status/quality of life scale and six single item scales (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). All the scales and single-item measures range in score from 0 to 100. A high score for a functional scale and global health status represents a high/healthy level of functioning, but a high score for a symptom scale/item represents a high level of symptomatology/problems. CR38 is a module complementary to C30, comprising 38 questions related to common symptoms and adverse effects of treatment related to colorectal cancer and has been validated for Brazilian patients (31). C30SumScore was calculated as a mean of all the functional and symptom scores excepting Global Health Status and Financial Problems as recommended by the authors, compiling the mean scores of a total of 13 domains. To calculate C30SumScore, the eight symptom scales scores were inverted, a high score meaning few symptoms and better outcomes. Wexner score (32), that has been validated for Portuguese(33) comprises 5 questions for fecal incontinence, producing a score from 0 to 20 and it was accessed at T4.

Sample size calculation and randomization

The study was primarily designed to compare clinical downstaging between the two treatment groups. Assuming 90% of downstaging with capecitabine and 70% with bolus 5-Fu/Lv, the estimated sample size was 48 patients in each arm (alpha: 0.05; beta: 80%). Time for accrual was stipulated in 24 months. Randomization was performed in a proportion 1:1 using R software (R Development Core Team, 2008) with permuted blocks stratified by tumor distance from AV: >5 cm or ≤5 cm.

Statistical analysis
All statistical analysis was performed using SPSS version 21.0 (SPSS Inc., California, USA). Continuous variables were displayed as means ± Standard Deviation (SD) or median with range (minimum and maximum) according to data distribution. Chi-square tests or Fisher exact tests were used to compare categorical variables, Student’s T test to compare means of parametrical variables and the Mann-Whitney U test to compare values of non-parametric data. To compare mean QOL scores between treatment arms the ANCOVA covariance test adjusted for basal clinical data (age, sex, tumor localization and clinical stage) was used. For comparing longitudinal QOL results ANOVA test with Greenhouse-Geisser correction for lack of sphericity was employed. Mean differences of QOL were considered clinically significant if a minimum discrepancy of 10 points was found.

**Results**

63 patients were randomized between January 2011 and February 2013. All patients completed neoCRT with no severe toxicities except form one patient with Grade 3 diarrhea and abdominal cramps. One patient refused surgery after a complete clinical response. Two patients quitted the study during follow-up. Clinical information was available for 61 patients. 31 patients were assigned to neoadjuvant capecitabine (Group 1) and 30 to 5-Fu/Lv (Group 2). Baseline characteristics and treatment results are depicted in Table 1. Groups were similar at baseline, and clinical response (downstaging, sphincter preservation and Mandard tumor regression grade) was comparable after neoCRT (Table 1). QOL data from 61 patients were available at T0, 60 at T1, 57 at T2, 51 at T3 and 37 at T4. Reasons for no completion of questionnaires at a given moment were death (n=14), disease progression (n=6), no adherence to follow-up (n=3), and desire to quit the study (n=2). Supplementary Table 1 shows the number of patients available for each scale in 5 moments. Figure 3 illustrate the study flow chart. Supplementary Table 2 reports the mean C30 and CR38 scores in all domains including the C30SumScore.
Table 1
Clinical, surgical, and pathological data of patients in both groups of treatment.

| Patients Characteristics | Total N=61 | Group 1 (Cap) N=31 | Group 2 (5-Fu) N=30 | p-value |
|--------------------------|-----------|---------------------|---------------------|---------|
| **Gender**               |           |                     |                     |         |
| Male                     | 28 (45.9) | 15 (48.4)           | 13 (43.3)           | 0.692*  |
| Female                   | 33 (54.1) | 16 (51.6)           | 17 (56.7)           |         |
| **Ethnicity**            |           |                     |                     |         |
| White                    | 47 (77.0) | 22 (71.0)           | 25 (83.3)           | 0.337*  |
| Black                    | 6 (9.8)   | 3 (9.7)             | 3 (10.0)            |         |
| Mixed                    | 8 (13.1)  | 6 (19.4)            | 2 (6.7)             |         |
| **Age (mean, SD)**       | 58.5 (11.4) | 56.6 (13.4)      | 60.5 (8.6)          | 0.182#  |
| **BMI (mean, SD)**       | 26.8 (4.6) | 25.8 (4.3)          | 27.7 (4.7)          | 0.102#  |
| **Tumor ≤ 50 mm AV**     | 30 (49.2) | 14 (41.1)           | 16 (53.3)           | 0.523*  |
| **Tumor ≤ 10 mm DL**     | 14 (22.9) | 4 (12.9)            | 10 (33.3)           | 0.111*  |
| **Tumor obstructive**    | 17 (27.8) | 9 (29.0)            | 8 (26.6)            | 0.845*  |
| **Cm from AV (mean)**    | 4.3 (2.7) | 4.9 (2.8)           | 3.7 (2.4)           | 0.141#  |
| **Sphincter invasion (MRI)** | 13 (21.3) | 6 (19.3)           | 7 (23.3)            | 0.747*  |
| **Basal Clinical Stage (MRI)** | 3  | 3 | 0 | 0.129* |
| I                        | 23        | 13                  | 10                  |         |
| II                       | 35        | 15                  | 20                  |         |
| III                      |           |                     |                     |         |
| **Sphincter preservation** | 49 (81.6) | 25 (83.3)           | 24 (80.0)           | 0.111*  |
| **Sphincter preservation (tumors ≤ 5cm from AV)** | 20 (66.6) | 9 (64.2) | 11 (68.7) | 0.550*  |
| **Clinical Downstaging** | 37 (61.7) | 21 (70.0)           | 16 (53.3)           | 0.288*  |
| **pCR**                  | 10 (16.6) | 7 (23.3)            | 3 (10.0)            | 0.165*  |
| **Mandard 1-2**          | 21 (35.0) | 13 (43.3)           | 8 (26.6)            | 0.175*  |

Cap: capecitabine; 5-Fu: 5-Fluorouracil; SD: Standard deviation; BMI: Body mass Index; AV: anal verge; DL: dentate line; MRI: Magnetic Resonance Imaging; pCR: pathologic complete response; CRM +: circumferential resection margin <1mm. * Qui-square test # Student’s t-test.
| Patients Characteristics | Total N=61 | Group 1 (Cap) N=31 | Group 2 (5-Fu) N=30 | p-value |
|--------------------------|-----------|-------------------|---------------------|---------|
| CRM +                    | 9(15.0)   | 6(20.0)           | 3(10.0)             | 0.472*  |

Cap: capecitabine; 5-Fu: 5-Fluorouracil; SD: Standard deviation; BMI: Body mass Index; AV: anal verge; DL: dentate line; MRI: Magnetic Resonance Imaging; pCR: pathologic complete response; CRM +: circumferential resection margin <1mm. * Qui-square test #Student’s t-test.

Table 2 shows comparison of QOL scores and the C30SumScore between Group 1 and Group 2 using covariate adjustment for age, gender, clinical stage, and tumor localization before (T0) and after neoadjuvant treatment (T1). At T0, Group 1 patients reported more insomnia (12.3 pts mean difference) but reported less weight loss (-12.1 pts mean difference). After neoadjuvant treatment, no difference in QOL between patients receiving capecitabine or 5-Fu/Lv was shown in any score of C30 questionnaire, but patients in group 1 (capecitabine) reported less miccional problems (15.3 pts mean difference), less gastrointestinal problems (-15.3 pts mean difference), less defecation problems (11.8 pts mean difference) and more sexual satisfaction (13.3 pts mean difference) in CR38 questionnaire modules. C30SumScore was equivalent before and after neoCRT in the two study groups.
Table 2: Mean QOL scores (C30 and CR38) comparing Group 1 and 2 before (T0) and after (T1) neoCRT
| EORTC QLQ-C30 | T0 |  | T1 |  |
|---------------|----|---|----|---|
|               | Group 1 (n=31) | Group 2 (n=30) | p-value | Mean difference | Group 1 (n=31) | Group 2 (n=29) | p-value | Mean difference |
| Physical functioning | 85.2 | 88.0 | 0.577 | -2.8 | 86.4 | 88.3 | 0.503 | -2.9 |
| Role functioning | 80.6 | 82.0 | 0.849 | -1.4 | 91.7 | 89.9 | 0.720 | 1.8 |
| Cognitive functioning | 77.6 | 79.4 | 0.793 | -1.8 | 84.9 | 87.7 | 0.598 | -2.7 |
| Emotional functioning | 66.9 | 64.6 | 0.782 | 2.3 | 71.8 | 68.0 | 0.620 | 3.8 |
| Social functioning | 82.9 | 77.3 | 0.449 | 5.6 | 86.9 | 84.2 | 0.695 | 2.7 |
| Fatigue | 21.7 | 18.1 | 0.645 | 3.6 | 14.7 | 11.3 | 0.434 | 3.4 |
| Pain | 28.1 | 26.5 | 0.821 | 1.6 | 19.6 | 11.6 | 0.256 | 7.9 |
| Dyspnea | 10.0 | 4.0 | 0.386 | 6.0 | 9.1 | 3.8 | 0.291 | 5.3 |
| Insomnia | 29.0 | 16.7 | 0.244 | 12.3 | 15.6 | 18.5 | 0.714 | -2.9 |
| Appetite Loss | 21.9 | 12.6 | 0.144 | 9.3 | 10.9 | 3.3 | 0.213 | 7.5 |
| Nausea | 2.1 | 5.8 | 0.258 | -3.7 | 0.0 | 0.0 | - | 0 |
| Constipation | 33.6 | 25.4 | 0.477 | 8.2 | 11.0 | 16.5 | 0.517 | 5.4 |
| Diarrhea | 24.0 | 17.3 | 0.475 | 6.6 | 4.1 | 7.7 | 0.361 | -3.5 |
| Financial difficulties | 31.8 | 37.2 | 0.612 | 5.4 | 21.1 | 27.3 | 0.514 | -6.2 |
| Global Health Status | 71.6 | 64.2 | 0.200 | 7.4 | 77.5 | 76.4 | 0.851 | 1.0 |
| C30SumScale | 78.8 | 81.8 | 0.450 | -3.0 | 87.4 | 88.2 | 0.788 | -0.8 |
| EORTC CR38 | T0 |  | T1 |  |
|               | Group 1 (n=31) | Group 2 (n=30) | p-value | Mean difference | Group 1 (n=31) | Group 2 (n=29) | p-value | Mean difference |
| Miccional problems | 30.8 | 38.8 | 0.373 | -5.0 | 30.7 | 46.1 | 0.525 | -15.3 |
| Gastrointestinal problems | 24.0 | 20.4 | 0.518 | 3.6 | 7.6 | 22.8 | 0.096 | -15.3 |
| Weight Loss | 24.8 | 36.9 | 0.267 | -12.1 | 12.7 | 21.3 | 0.274 | -8.6 |
| Chemotherapy side effects | 16.7 | 9.7 | 0.240 | 7.0 | 15.5 | 11.1 | 0.219 | 4.3 |
| QOL Domain                        | T0 | T1 | Adjusted p-value | T2 | T3 | Adjusted p-value |
|----------------------------------|----|----|------------------|----|----|------------------|
| Defecation problems              | 34.1| 35.9| 0.736            | -1.7| 15.5| 23.3            | 0.168           | -11.8|
| Male sexual problems*            | -  | -  | -                | -  | -  | -                | -               | -    |
| Female sexual problems*          | -  | -  | -                | -  | -  | -                | -               | -    |
| Stoma related problems*          | -  | -  | -                | -  | -  | -                | -               | -    |
| Body image                       | 8.8| 10.7| 0.742            | -1.9| 4.6 | 2.9              | 0.611           | 2.3  |
| Future perspectives              | 55.5| 63.3| 0.726            | -7.9| 57.4| 59.2             | 0.921           | -1.8 |
| Sexual functioning               | 48.5| 46.8| 0.883            | 1.6 | 62.5| 60.5             | 0.848           | 2.0  |
| Sexual satisfaction              | 55.3| 58.5| 0.827            | -3.2| 71.2| 57.9             | 0.333           | 13.3 |

QOL: Quality of Life; neoCRT: neoadjuvant chemoradiotherapy; using ANCOVA multivariate analysis adjusted for age, gender, tumor height and clinical stage. *: insufficient number of valid responses

The longitudinal QOL analysis comparing results on five different moments of treatment is depicted in Table 3. Median time intervals between evaluations were: T0 to T1 median 14 (11–18) weeks; T1 to T2 median 9 (4–19) weeks; T2 to T3 median 40 (28–95) weeks; T3 to T4 median 175 (102–227) weeks or 3.3 years. Also, the median time interval from rectal resection to T2 was five (4–15) weeks, and to T4 was 214 (148–262) weeks. Role functioning scores showed improvement after neoCRT (T1) compared to basal evaluation (T0) and worsened after a median time of five weeks (range 3-15 weeks) after surgical resection, decreasing 24.4 points at T2 evaluation. Patients also significantly improved at the late evaluation (T4) compared to postoperative period (T2). Patients also reported more fatigue and appetite loss after surgical resection (an increase of 15.4 and 17.1 points respectively T2 to T1). Constipation improved after neoCRT (reduction in 11.5 points comparing T0 to T1). Diarrhea was a symptom that worsened at T4 compared to T1 (an increase in 22.2 points), meaning that after stoma closure patients were more symptomatic in this domain than after the chemoradiation period. Both Global Health Status and the new C30SumScore detected improvement in T1 score compared to T0 (after chemoradiation versus basal scores), but only the C30SumScore detected difference in T2 compared to T1 (postoperative period compared to post chemoradiation), but this difference did not reach the 10-points range. Interestingly, Global Health Status score improved at T4 compared to T0 in 15.5 points, a difference that was not identified in any other domain of C30 questionnaire.
Table 3
Longitudinal comparison of QOL scores using ANOVA’s repeated measures test and Greenhouse-Geiser correction for lack of sphericity.

| EORTC QLQ-C30 | T0 | T1 | T2 | T3 | T4 | Sphericity | Anova (G.Geisser) | Difference |
|---------------|----|----|----|----|----|------------|-------------------|------------|
| Physical functioning | 87.9 | 85.2 | 78.4 | 81.0 | 86.7 | 0.353 | F(3.47-125.01)=2.60; p=0.047 | No |
| Role functioning | 81.0 | 90.1 | 65.7 | 82.0 | 83.8 | 0.000 | F(3.00-108.18)=5.93; p=0.001 | T0<T1; T1>T2; T2<T4 |
| Cognitive functioning | 79.3 | 86.9 | 81.1 | 81.1 | 77.4 | 0.540 | F(3.61-129.91)=1.64; p=0.174 | No |
| Emotional functioning | 64.2 | 73.0 | 67.8 | 68.0 | 70.7 | 0.007 | F(3.05-109.82)=1.17; p=0.322 | No |
| Social functioning | 73.8 | 87.7 | 73.2 | 80.3 | 77.2 | 0.484 | F(3.64-134.65)=2.29; p=0.069 | No |
| Fatigue | 18.7 | 15.1 | 30.5 | 20.7 | 15.4 | 0.305 | F(3.43-119.96)=5.28; p=0.001 | T2>T1 |
| Pain | 27.0 | 19.4 | 23.4 | 21.2 | 16.7 | 0.881 | F(3.77-135.62)=1.23; p=0.298 | No |
| Dyspnea | 4.6 | 3.7 | 1.8 | 3.7 | 4.6 | 0.002 | F(2.92-102.3)=0.307; p=0.815 | No |
| Insomnia | 19.8 | 21.6 | 30.6 | 26.1 | 21.6 | 0.010 | F(3.11-112.08)=1.05; p=0.375 | No |
| Appetite Loss | 12.6 | 6.3 | 23.4 | 11.7 | 7.2 | 0.001 | F(2.90-104.673)=3.94; p=0.011 | T2>T1 |
| Nausea | 4.1 | 0.0 | 3.2 | 5.0 | 2.7 | 0.000 | F(2.27-81.89)=2.15; p=0.116 | No |
| Constipation | 24.8 | 13.3 | 4.7 | 4.7 | 13.3 | 0.000 | F(2.86-97.40)=4.69; p=0.005 | T0>T2; T0>T3 |
| Diarrhea | 21.3 | 6.5 | 13.9 | 15.7 | 28.7 | 0.035 | F(3.26-114.06)=3.34; p=0.019 | T4>T1 |

N.A.: not applicable due to insufficient number of patient answers.
| EORTC QLQ-C30 | T0   | T1   | T2   | T3   | T4   | Sphericity | Anova (G.Geisser) | Difference            |
|---------------|------|------|------|------|------|------------|------------------|----------------------|
| Financial difficulties | 35.1 | 24.3 | 33.3 | 25.2 | 26.1 | 0.384 | F(3.51-126.23)=1.40; p=0.243 | No                   |
| Global Health Status | 64.7 | 74.3 | 71.6 | 75.2 | 80.2 | 0.364 | F(3.53-127.07)=4.37; p=0.004 | T0<T1; T0<T4          |
| C30SumScale   | 81.3 | 87.4 | 79.6 | 83.5 | 83.4 | 0.001 | F(3.08-110.99)=3.195; p=0.025 | T0<T1; T1>T2          |

| EORTC CR38 | T0   | T1   | T2   | T3   | T4   | p value |                      |
|------------|------|------|------|------|------|---------|----------------------|
| Miccional problems | 38.1 | 41.4 | 45.6 | 39.0 | 32.4 | 0.089 | F(3.43-123.65)=2.83; p=0.035 | T2>T4                |
| Gastrointestinal problems | 21.1 | 15.7 | 16.9 | 16.9 | 19.1 | 0.440 | F(3.56-128.26)=1.07; p=0.368 | No                   |
| Weight Loss | 34.2 | 16.7 | 39.8 | 16.7 | 11.1 | 0.640 | F(3.62-126.73)=8.05; p=0.001 | T0>T4; T1<T2; T2>T3; T4>T4 |
| Chemotherapy side effects | 10.2 | 12.6 | 16.1 | 14.4 | 17.4 | 0.090 | F(3.17-114.431)=1.65; p=0.179 | No                   |
| Defecation problems | 30.1 | 15.3 | -    | -    | 19.1 | 0.318 | F(1.76-29.99)=6.93; p=0.004 | T0>T1; T0>T4         |
| Male sexual problems | 0.0  | 27.1 | 52.1 | 50.0 | 47.9 | 0.090 | F(2.47-17.28)=3.74; p=0.037 | T0<T4                |
| Female sexual problems | -    | -    | -    | -    | -    | -      | N.A.                 |
| Stoma related problems | -    | -    | 31.1 | 35.5 | 36.8 | 0.689 | F(1.85-18.53)=0.39; p=0.668 | No                   |
| Body image   | 14.1 | 12.9 | 34.4 | 38.1 | 24.9 | 0.028 | F(3.27-117-84)=9.60; p<0.001 | T0<T2; T0<T3; T1<T2; T1<T3 |
| Future perspectives | 68.5 | 59.3 | 61.1 | 49.1 | 50.9 | 0.001 | F(2.8-98.3)=1.71; p=0.171 | No                   |

N.A.: not applicable due to insufficient number of patient answers.
Regarding the CR38 modules specific for colorectal cancer, the longitudinal analysis detected improvement in the late evaluation period (T4) compared to postoperative period (T2) in the following domains: miccional problems (-13.2 pts mean difference); weight loss (-28.7 points mean difference); and sexual functioning (15.5 points mean difference). Comparing the evaluation before treatment (T0) with the available patients at late evaluation at T4, there was a difference at Global Heath Status (15.5 pts mean difference); weigh loss (-23.1 pts mean difference), reduction in defecation problems (-11.0 pts mean difference) but an increase in male sexual problems (47.9 points mean difference).

Graphic 1 shows temporal changes in QOL using the C30SumScore for each treatment group and for all patients at the five moments of evaluation.

Excluding patients with definitive stoma (n= 8), patients that had no bowel continuity restored (n=4) and patients who had recurrences (n= 16), 27 patients were evaluated using Wexner score at T4 with a mean of 9.2 points (SD 4.1). No difference in mean incontinence score was found comparing ISR to LAR (10.0 vs 9.1, p=0.663)., There were no association between level of anastomosis and incontinence assuming the Wexner score value of 10 as cutoff (p=0.415). Patients with Wexner Score ≥ 10 had more symptoms of diarrhea (p=0.006) and defecation problems (p=0.004) in QOL scores at T4 (Table 4).
Table 4
Mean QOL scores comparing patients with Wexner Score <10 vs ≥10. Statistically significant values were displayed in bold.

| EORTC QLQ-C30                  | Wexner<10 | Wexner≥10 | Mean Difference | p-value |
|--------------------------------|-----------|-----------|-----------------|---------|
| Physical functioning           | 88.2      | 87.6      | 0.6             | 0.930   |
| Role functioning               | 91.0      | 79.8      | 11.3            | 0.250   |
| Cognitive functioning          | 85.9      | 71.4      | 14.5            | 0.140   |
| Emotional functioning          | 75.0      | 65.5      | 9.5             | 0.354   |
| Social functioning             | 89.8      | 73.8      | 15.9            | 0.140   |
| Fatigue                        | 11.1      | 19.8      | -8.7            | 0.202   |
| Pain                           | 19.2      | 20.2      | -1.0            | 0.935   |
| Dyspnea                        | 5.1       | 7.1       | -2.0            | 0.754   |
| Insomnia                       | 15.4      | 11.9      | 3.5             | 0.677   |
| Appetite Loss                  | 2.6       | 5.1       | -2.6            | 0.558   |
| Nausea                         | 1.3       | 4.8       | -3.5            | 0.395   |
| Constipation                   | 15.4      | 14.3      | 1.1             | 0.906   |
| Diarrhea                       | 15.4      | 52.4      | -37.0           | 0.006   |
| Financial difficulties         | 25.6      | 28.6      | -2.9            | 0.851   |
| Global Health Status           | 84.6      | 70.8      | 13.8            | 0.077   |
| C30SumScale                    | 88.0      | 80.1      | 8.0             | 0.201   |

| EORTC CR38                     | Wexner<10 | Wexner≥10 | Mean Difference | p-value |
|--------------------------------|-----------|-----------|-----------------|---------|
| Miccional problems             | 25.6      | 38.9      | -13.3           | 0.080   |
| Gastrointestinal problems      | 15.9      | 27.1      | -11.3           | 0.109   |
| Weight Loss                    | 2.6       | 15.4      | -12.8           | 0.105   |
| Chemotherapy side effects      | 11.1      | 21.4      | -10.3           | 0.187   |
| Defecation problems            | 14.7      | 31.5      | -16.9           | 0.004   |
| Male sexual problems           | 46.7      | 50.0      | -3.3            | 0.868   |
| Female sexual problems         | 38.9      | 50.0      | -11.1           | 0.874   |
| Stoma related problems         | NA        | NA        | NA              | NA      |
| Body image                     | 22.2      | 25.4      | -3.2            | 0.779   |
| Future perspectives            | 50.0      | 59.5      | -9.5            | 0.556   |
| EORTC QLQ-C30 | Wexner<10 | Wexner≥10 | Mean Difference | p-value |
|--------------|----------|----------|----------------|---------|
| Sexual functioning | 18.0 | 32.2 | -14.2 | 0.179 |
| Sexual satisfaction | 33.3 | 46.7 | -13.3 | 0.524 |

Conclusions

- The two neoCRT regimens using either oral capecitabine or intravenous bolus 5-Fu/Lv combined to radiotherapy achieved comparable clinical and pathological response rates.
- QOL was equivalent between groups after neoCRT except for miccional problems, gastrointestinal problems, defecation problems and sexual satisfaction favoring the capecitabine arm.
- QOL was improved after neoCRT but decreased following rectal resection.
- Wexner score was high after sphincter preservation (mean 9.2 points) and was equivalent comparing LAR versus ISR.
- C30SummaryScore was a useful tool to detect statistical differences in overall QOL comparing different phases of protocol treatment.

Discussion

The contemporary treatment for LARC provides long-term survival in most patients, but acute and late sequelae are major setbacks and jeopardize the successfulness of medical interventions. Investigation on new treatment strategies should maintain efforts to improve disease control rates, but optimization of the quality of life after successful treatment becomes a prime directive. In consonance, our randomized study was designed to compare clinical response between capecitabine and 5-Fu/Lv combined to radiotherapy in neoadjuvant setting, but also included a dedicated QOL analysis. In the present study we assumed that EORTC’s QOL scores would reflect clinical differences in disease responses according to treatment group results. After neoadjuvant treatment, despite no difference in QLQ-C30 scores between patients receiving capecitabine or 5-Fu/Lv was found, patients in group 1 (capecitabine) reported less miccional problems (15.3 pts mean difference), less gastrointestinal problems (-15.3 pts mean difference), less defecation problems (11.8 pts mean difference) and more sexual satisfaction (13.3 pts mean difference) in CR38 questionnaire specific colorectal modules. Coincidently, the clinical response rate (70.0% vs 53.3%) and the pathological complete response rate (23.3% vs 10.0%) were higher in the capecitabine group, although not statistically which might have been explained by the sample size enrolled in the study. No previous publications compared QOL after these two drug regimens in neoadjuvant setting, but some reports compared these two drugs in adjuvant or palliative settings. A nonrandomized Taiwanese study published in 2015 evaluated 123 elderly stage III patients after adjuvant CT compared QOL and treatment costs of capecitabine vs 5-Fu/Lv, associated or not to oxaliplatin. After adjusting confounding variables and baseline characteristics, QOL using capecitabine was not inferior to 5-Fu/Lv and reduced costs. In accordance, two previous studies compared palliative treatment in metastatic colorectal cancer using capecitabine and 5-Fu/Lv in combination to oxaliplatin showed no difference in QOL between treatment groups. Nevertheless, comparing the moments before and after neoCRT we balanced the effect of
surgical resection and excluded the interference of oxaliplatin, which allowed a direct comparison of the two drugs in combination to radiotherapy.

The second question to be answered was regarding the functional results after sphincter preservation, which was an important endpoint in our study. Combining accurate preoperative imaging (MRI and EUS) to modern surgical techniques, the sphincter preservation rate was 81.6% in our study, considering all patients. We have accomplished to reestablish the intestinal continuity using coloanal anastomosis and/or intersphincteric resection after good clinical responders even with low rectal cancers close to sphincter complex, although our functional results were often suboptimal (mean Wexner score of 9.2). Interestingly, no functional difference was observed after ISR compared to LAR.

Both neoadjuvant schemes were effective in ameliorating general cancer symptoms and health status after neoCRT(T1) compared to baseline (T0), expressed as improvements in role functioning, global health status and C30SumScore scales of QLQ C30 and reduction in defecation problems of CR38 questionnaire, and no worsening of any domain of both questionnaires. In contrast, the adverse effects of rectal resection in QOL were evident: four of the C30 scales and three of the CR38 scales had worse scores comparing T1 to T2. Not surprisingly, patients had nonsignificant improvement in QOL six months after rectal resection, except for weight loss and sexual functioning despite receiving many cycles of adjuvant chemotherapy from T2 to T3. This time interval may have allowed improvement in patients perception of surgical morbidity. And although our sphincter preservation rate was over 80%, patients had to deal with temporary stomas for at least six months.

Finally, we included a late fecal continence evaluation one year after stoma reversal using the Wexner score, which has been recently translated and validated in Portuguese(33). We found an average high score of fecal incontinence that did not correlate to anastomosis level but correlated to QOL scores of diarrhea and defecation problems.

Our participants have never recovered from some sequelae of the treatment even at late evaluation after a median time interval of 49 months. Comparing to basal evaluation(T0), patients improved from general cancer symptoms (Global Health Status), ameliorated on weight loss and constipation, but developed male sexual dysfunction. Comparing the late evaluation (T4) to the postoperative period (T2), patients had improvement in role functioning, weight loss, miccional problems and sexual functioning, which may reflect that some autonomic sequelae can ameliorate with time, but also can reflect a tendency of patients to change the perception of the same condition over time, for example if their cancer is controlled, a phenomenon called “response shift”(37, 38). The literature supports the findings of symptom improvement over time. A study from the Netherlands identified worse C30SumScore, physical functioning, fatigue and dyspnea in patients who received adjuvant chemotherapy compared to observation, but this difference disappeared 12 months after surgery(39). Other studies demonstrate stabilization of LARS one year after surgery(40) and that patients after long time follow-up still present significant disfunction (41).

Concerning the specific colorectal cancer module, the CR38 was commonly used in adjunct to QLQ-C30 to measure specific domains of quality of life in colorectal cancer patients, but criticism has emerged because questions concerning sexuality are often unanswered on CR38; these questions were suppressed or revised
in the CR29 version(22). CR29 emerged later and was in validation when we started our study. Indeed, in our study few patients answered questions about sexual problems (only were 4 available to compare T0 and T1) and sexual satisfaction (only 19 of 61 were available).

Our study was the first to use the C30SumScore to compare results of QOL over time in five moments beginning at pretreatment levels, and it detected significant differences in QOL after neoCRT and rectal resection. After neoCRT patients reported an increase in 6.1 points in C30SumScore and after rectal resection a decrease in 7.8 points in mean scores. The C30SumScore appears to add relevant information to clinical practice allowing comparison between treatment groups and detecting relevant temporal changes in QOL.

Unfortunately, our study leaves unanswered an old dilemma concerning better selection of patients for sphincter preservation after low rectal cancer resection. We did not detect differences in Wexner scores comparing patients with LAR to ISR, and both groups showed moderate to high levels of incontinence (mean 9.1 versus 10.0 points, respectively). A meta-analysis published in 2015 including 13 studies from 2001 to 2015 comprised data from 1805 patients using QLQ-C30 and CR38(23). Their main objective was to compare QOL in patients submitted to LAR vs APR, and QOL questionnaires were applied after 12 months of surgery. Patients with sphincter preservation had better social functioning, better body image but more symptoms of constipation. One study from Spain evaluated QOL compared APR versus LAR in 84 patients after neoCRT and Surgery (42). After a mean follow up of 48.7 months, no difference in QLQ-C30 scores was detected. Using the CR29 questionnaire, only stool frequency score was increased in LAR patients (33.3 vs 14.3 points). Another study compared QOL and functional results using Wexner score in 14 patients submitted to ISR versus 22 patients submitted to APR and perineal colostomy(43). ISR patients had worse Physical Functioning (84.1 vs 100.0 points) but less Defecation Problems compared to perineal colostomy (57.1 vs 90.5 points). Wexner score was similar between two groups (median 11 in ISF versus 10 in APR), which was comparable to our results of ISR (median Wexner score of 10). A matched group analysis from Heidelberg, Germany, compared QOL results of LAR, ISR and APR in 131 patients from a prospective database (44). They found that physical functioning scores were better after LAR and ISR compared to APR (82.2 and 80.2 vs 69.9 points), but constipation and diarrhea were both more frequent in LAR and ISR compared to APR. ISR had mean higher Wexner score compared to LAR (12.9 vs 9.5), a difference that was not significant in our series. A previous study from Illinois, USA, also found better physical functioning scores after sphincter preservation in a retrospective study (94 vs 87 points) but also more constipation (16 vs 8 points) and decreased sexual functioning (27 vs 76 points)(44). These suboptimal functional results after curative resection of low rectal cancer motivates investigation of less aggressive approaches to good clinical responders, including the nonoperative management that has been explored in recent literature, including our own institution’s experience(45, 46).

New strategies are under investigation to decrease toxicity and QOL impairment. Avoiding radiotherapy would probably reduce a degree of pelvic toxicity ameliorating anorectal function after rectal resection, and some studies demonstrated promising response rates using isolated neoadjuvant chemotherapy(47, 48). One tendency in investigation by our group is the total neoadjuvant treatment, in which all cycles of systemic chemotherapy are delivered before rectal resection with the addition of short-course radiotherapy.
This strategy is aimed to improve response, increase compliance rates, prevent distant relapse, allows stoma reversal one month after TME, and the possibility of organ preservation after clinical complete response.

Finally, our study was limited due to incomplete accrual which may have limited the statistical power to detect small outcome differences between the two treatment arms, as only 63 of 96 patients were randomized after two years because some stage I and many Stage IV patients were later excluded after ultimate radiological review. Nevertheless, we were able to show significant difference in QOL in different phases of treatment combining the two treatment arms. We also did not include manometric evaluation, which would give additional information regarding the suitable candidates to sphincter preservation in low rectal cancer cases. Despite this possible caveat, manometry is not widely available as it depends on dedicated equipment and expertise, and many QOL of studies after rectal cancer treatment do not report manometry data. Most studies, including ours, focus on patient reported outcomes, as the Wexner scale and EORTC questionnaires, which make our results comparable to literature and applicable into clinical practice.

List Of Abbreviations

5-Fu/Lv: 5-Fluorouracil and Leucovorin
AJCC: American Joint Commission on Cancer
APR: Abdominoperineal Resection
AV: Anal Verge
C30SumScore: C30 Summary Score
CT: Computer Tomography
CTCAE: Common Terminology for Adverse Events
EORTC: European Organization for Research and Treatment of Cancer
EUS: Endorectal Ultrasound
INCA: Instituto Nacional de Cancer (National Cancer Institute of Brazil)
ISR: Intersphincteric Resection
LAR: Low Anterior Resection
LARC: Locally Advanced Rectal Cancer
LARS: Low Anterior Resection Syndrome
MRI: Magnetic Resonance Imaging
Declarations

**Ethical Approval and Consent to participate:** this was a prospective study approved by Ethics Committee of National Cancer Institute of Brazil (INCA) in 2010 under register number 83/10 (NCT03428529). All patients voluntarily agreed to participate after informed consent.

**Consent for publication:** all authors declare that they consented to submit the paper.

**Availability of supporting data:** the datasets during and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Competing interests:** all authors declare that they have no conflicts of interests and consented to submit the paper.

**Funding:** the present study was totally supported by the Division of Clinical Research and Technological Development of the National Cancer Institute of Brazil, subordinated to the Ministry of Health of Brazil.

**Authors' contributions:** all the Authors made substantial contributions to the manuscript as follows:

- Study concepts: Carlos Gil Ferreira and Eduardo Linhares.
- Study design: Fernando Meton Vieira, Rodrigo Otavio de Castro Araujo, Ana Paula Ornellas.
- Data acquisition: Rodrigo Otavio de Castro Araujo, Simone Guaraldi and Claudia Carrada.
- Quality control of data and algorithms: Ana Paula Ornellas, Ivanir Martins, Claudia Carrada.
- Data analysis and interpretation: Rodrigo Otavio de Castro Araujo e Luiz Claudio Santos Thuler.
- Statistical analysis: Rodrigo Otavio de Castro Araujo e Luiz Claudio Santos Thuler.
- Manuscript preparation: Rodrigo Otavio de Castro Araujo.
- Manuscript editing: Marcus Vinicius Valadão and Simone Guaraldi.
- Manuscript review: All the authors above.

**Acknowledgements:** We would like to thank all the supporting team of the mentioned Division, especially Dr. Andreia Cristina de Melo, Isabelle Small, Giovana Kovalesky, Alexandre de Souza Fonseca, Cecilia Ferreira da Silva, and all the staff involved in the protocol.

**Availability of data and materials:** The datasets during and/or analyzed during the current study are publicly available at Mendeley dataset as: Araujo, Rodrigo Otavio (2021), “INCAGI004”, Mendeley Data, V1, doi: 10.17632/75vdm7phv9.1.
Acknowledgements: The present study was totally supported by the Division of Clinical Research and Technological Development of the National Cancer Institute of Brazil, subordinated to the Ministry of Health of Brazil. We would like to thank all the supporting team of the mentioned Division, especially Dr. Andreia Cristina de Melo, Isabelle Small, Giovana Kovalesky, Alexandre de Souza Fonseca, Cecilia Ferreira da Silva, and all the staff involved in the protocol.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians [Internet]. 2018 Nov [cited 2020 Dec 5];68(6):394–424. Available from: https://pubmed.ncbi.nlm.nih.gov/30207593/

2. Instituto Nacional de Câncer José Alencar Gomes da Silva (2017) Estimativa 2018: incidência de câncer no Brasil. INCA, Rio de Janeiro, 128 p

3. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR et al. AJCC Cancer Staging Manual (8th edition). 8th ed. Springer International Publishing: American Joint Commission on Cancer; 2017

4. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R et al (2004) Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer. New England Journal of Medicine [Internet]. Oct 21;351(17):1731–40. Available from: https://doi.org/10.1056/NEJMoa040694

5. Hofheinz R-D, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT et al (2012 Jun) Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. The Lancet Oncology 13(6):579–588

6. Kim JS, Kim JS, Cho MJ, Yoon WH, Song KS (2006 Feb) Comparison of the efficacy of oral capecitabine versus bolus 5-FU in preoperative radiotherapy of locally advanced rectal cancer. J Korean Med Sci 21(1):52–57

7. Saif MW, Hashmi S, Zelterman D, Almhanna K, Kim R (2008 Feb) Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review. Int J Colorectal Dis 23(2):139–145

8. Allegra CJ, Yothers G, O’Connell MJ, Beart RW, Wozniak TF, Pitot HC et al. Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: A phase III randomized clinical trial. Journal of the National Cancer Institute. 2015;107(11)

9. O’Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S et al (2014 Jun) Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 32(18):1927–1934

10. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H. X-Ray Irradiation Induces Thymidine Phosphorylase and Enhances the Efficacy of Capecitabine (Xeloda) in Human Cancer Xenografts. Clinical Cancer Research. 1999;5(10)
11. Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L et al (2000) Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45(4):291–297

12. Twelves C, Boyer M, Findlay M, Cassidy J, Weitzel C, Barker C et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. European journal of cancer (Oxford, England: 1990). 2001 Mar;37(5):597–604

13. Heald RJ, Moran BJ, Ryall RDH, Sexton R, MacFarlane JK. Rectal Cancer: The Basingstoke experience of total mesorectal excision, 1978-1997. Archives of Surgery [Internet]. 1998 Aug [cited 2021 Mar 20];133(8):894–9. Available from: https://pubmed.ncbi.nlm.nih.gov/9711965/

14. Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D et al (2015) Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): Final results of the multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology [Internet]. Aug 1 [cited 2021 Mar 20];16(8):979–89. Available from: https://linkinghub.elsevier.com/retrieve/pii/S147020451500159X

15. Miles WE (1931) The Present Position of the Radical Abdomino-Perineal Operation for Cancer of the Rectum in Regard to Mortality and Post-operative Recurrence. Proceedings of the Royal Society of Medicine. May;24(7):989–91

16. Rullier E, Denost Q, Vendrely V, Rullier A, Laurent C. Low Rectal Cancer. Diseases of the Colon & Rectum [Internet]. 2013 May [cited 2021 Mar 20];56(5):560–7. Available from: https://journals.lww.com/00003453-201305000-00004

17. Engel J, Kerr J, Schlesinger-Raab A, Eckel R, Sauer H, Hölzel D. Quality of Life in Rectal Cancer Patients. Annals of Surgery [Internet]. 2003 Aug [cited 2021 Mar 20];238(2):203–13. Available from: /pmc/articles/PMC1422675/

18. Havenga K, Enker WE, McDermott K, Cohen AM, Minsky BD, Guillem J (1996 Jun) Male and female sexual and urinary function after total mesorectal excision with autonomic nerve preservation for carcinoma of the rectum. J Am Coll Surg 182(6):495–502

19. Ridolfi TJ, Berger N, Ludwig KA (2016) Low Anterior Resection Syndrome: Current Management and Future Directions. [cited 2021 Mar 20]; Available from: http://dx.doi.org/

20. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al. The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute [Internet]. 1993 Mar 3 [cited 2021 Mar 20];85(5):365–76. Available from: https://pubmed.ncbi.nlm.nih.gov/8433390/

21. Sprangers MA, te Velde A, Aaronson NK. The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). European Organization for Research and Treatment of Cancer Study Group on Quality of Life. European journal of cancer (Oxford, England: 1990). 1999 Feb;35(2):238–47

22. Whistance RN, Conroy T, Chie W, Costantini A, Sezer O, Koller M et al. Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in
patients with colorectal cancer. European journal of cancer (Oxford, England: 1990). 2009 Nov;45(17):3017–26

23. Maslyankov S, Penchev D, Todorov G, Vladov N. A Meta-Analysis of Quality of Life, Estimated by Questionnaires of the European Organization for Research and Treatment of Cancer (EORTC) after Rectal Cancer Surgery. Chirurgia (Bucharest, Romania: 1990). 2015;110(4):356–61

24. Grumann MM, Noack EM, Hoffmann IA, Schlag PM. Comparison of Quality of Life in Patients Undergoing Abdominoperineal Extirpation or Anterior Resection for Rectal Cancer. 2001

25. Phillips R, Gandhi M, Cheung YB, Findlay MP, Win KM, Hai HH et al. Summary scores captured changes in subjects’ QoL as measured by the multiple scales of the EORTC QLQ-C30. Journal of clinical epidemiology. 2015 Aug;68(8):895–902

26. Giesinger JM, Kieffer JM, Fayers PM, Groenvold M, Petersen MA, Scott NW et al. Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. Journal of Clinical Epidemiology. 2016 Jan 1;69:79–88

27. Pompili C, Koller M, Velikova G, Franks K, Absolom K, Callister M et al. EORTC QLQ-C30 summary score reliably detects changes in QoL three months after anatomic lung resection for Non-Small Cell Lung Cancer (NSCLC). Lung cancer (Amsterdam, Netherlands). 2018 Sep;123:149–54

28. Husson O, Rooij BH, Kieffer J, Oerlemans S, Mols F, Aaronson NK et al. The EORTC QLQ-C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the “Real-World”: Results from the Population-Based PROFILES Registry. The Oncologist. 2020 Apr;25(4)

29. AJCC Cancer Staging Handbook - From the AJCC Cancer Staging Manual | Stephen Edge | Springer [Internet]. [cited 2020 Dec 7]. Available from: https://www.springer.com/gp/book/9780387884424

30. Paiva CE, Carneseca EC, Barroso EM, de Camargos MG, Alfano ACC, Rugno FC et al (2014 Aug) Further evaluation of the EORTC QLQ-C30 psychometric properties in a large Brazilian cancer patient cohort as a function of their educational status. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer 22(8):2151–2160

31. Souza R, Barros C, Souza R, Cesar M, Rosa D, Bin F et al (2005) Avaliação Da Qualidade De Vida De Doentes De Carcinoma Retal, Submetidos À Ressecção Com Preservação Esfínteriana Ou À Amputação Abdominoperineal. Rev Bras Coloproct 25(3):235–240

32. Rusavy Z, Jansova M, Kalis V (2014) Anal incontinence severity assessment tools used worldwide. International Journal of Gynecology & Obstetrics [Internet]. Aug 1;126(2):146–50. Available from: https://doi.org/10.1016/j.ijgo.2014.02.025

33. Fonseca AM, Meinberg MF, Lucas DV, Monteiro MV, Figueiredo EM, Fonseca L et al (2016 Jun) Cultural adaptation and validation of the Wexner scale in patients with anal incontinence in a Brazilian population. International urogynecology journal 27(6):959–963

34. Lin JK, Tan CHE, Yang MC. Comparing the effectiveness of capecitabine versus 5-fluorouracil/leucovorin therapy for elderly Taiwanese stage III colorectal cancer patients based on quality-of-life measures (QLQ-C30 and QLQ-CR38) and a new cost assessment tool. Health and Quality of Life Outcomes [Internet]. 2015 May 19 [cited 2021 Mar 27];13(1):61. Available from: http://hqlo.biomedcentral.com/articles/10.1186/s12955-015-0261-1
35. Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF et al (2011 May) Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomized factorial trial. Lancet 377(9779):1749–1759

36. Conroy T, Hebbar M, Bennouna J, Ducreux M, Ychou M, Llédo G et al (2010 Jan) Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer. British journal of cancer 102(1):59–67

37. Rapkin BD, Schwartz CE (2019) Advancing quality-of-life research by deepening our understanding of response shift: a unifying theory of appraisal, vol 28. Quality of Life Research. Springer International Publishing, pp 2623–2630

38. Schwartz CE, Sprangers MAG. Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research. In: Social Science and Medicine [Internet]. Soc Sci Med; 1999 [cited 2021 Mar 27]. p. 1531–48. Available from: https://pubmed.ncbi.nlm.nih.gov/10400255/

39. van der Valk MJM, Hilling DE, Meershoek-Klein Kranenburg E, Peeters KCMJ, Kapiteijn E, Tsonaka R et al (2019) Quality of Life after Curative Resection for Rectal Cancer in Patients Treated with Adjuvant Chemotherapy Compared with Observation: Results of the Randomized Phase III SCRIPT Trial. Dis Colon Rectum 62(6):711–720

40. Sturiale A, Martellucci J, Zurli L, Vaccaro C, Brusciano L, Limongelli P et al. Long-term functional follow-up after anterior rectal resection for cancer. International Journal of Colorectal Disease [Internet]. 2017 Jan 1 [cited 2021 Mar 27];32(1):83–8. Available from: https://pubmed.ncbi.nlm.nih.gov/27695976/

41. Pieniowski EHA, Palmer GJ, Juul T, Lagergren P, Johar A, Emmertsen KJ et al. Low Anterior Resection Syndrome and Quality of Life after Sphincter-Sparing Rectal Cancer Surgery: A Long-term Longitudinal Follow-up. Diseases of the Colon and Rectum [Internet]. 2019 Jan 1 [cited 2021 Mar 27];62(1):14–20. Available from: https://journals.lww.com/00003453-201901000-00005

42. Dumont F, Ayadi M, Goéré D, Honoré C, Elias D (2013 Sep) Comparison of fecal continence and quality of life between intersphincteric resection and abdominoperineal resection plus perineal colostomy for ultra-low rectal cancer. Journal of surgical oncology 108(4):225–229

43. Konanz J, Herrle F, Weiss C, Post S, Kienle P (2013 May) Quality of life of patients after low anterior, intersphincteric, and abdominoperineal resection for rectal cancer—a matched-pair analysis. Int J Colorectal Dis 28(5):679–688

44. Kasparek MS, Hassan I, Cima RR, Larson DR, Gullerud RE, Wolff BG (2011 Aug) Quality of life after coloanal anastomosis and abdominoperineal resection for distal rectal cancers: sphincter preservation vs quality of life. Colorectal disease: the official journal of the Association of Coloproctology of Great Britain Ireland 13(8):872–877

45. Araujo ROC, Valadão M, Borges D, Linhares E, de Jesus JP, Ferreira CG et al. Nonoperative management of rectal cancer after chemoradiation opposed to resection after complete clinical response. A comparative study. European Journal of Surgical Oncology. 2015;41(11)

46. Chadi SA, Malcomson L, Ensor J, Riley RD, Vaccaro CA, Rossi GL et al. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in
rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. The Lancet Gastroenterology and Hepatology. 2018;3(12)

47. Kamiya T, Uehara K, Nakayama G, Ishigure K, Kobayashi S, Hiramatsu K et al. Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study. European Journal of Surgical Oncology [Internet]. 2016 Jun 1 [cited 2021 Mar 20];42(6):829–35. Available from: https://pubmed.ncbi.nlm.nih.gov/26968228/

48. Hasegawa S, Goto S, Matsumoto T, Hida K, Kawada K, Matsusue R et al. A Multicenter Phase 2 Study on the Feasibility and Efficacy of Neoadjuvant Chemotherapy Without Radiotherapy for Locally Advanced Rectal Cancer. Annals of Surgical Oncology [Internet]. 2017 Nov 1 [cited 2021 Mar 19];24(12):3587–95. Available from: https://pubmed.ncbi.nlm.nih.gov/28685354/

**Figures**

**Study Design**

![Study Design Diagram](image)

*Informed consent*
*Basal staging with thorax and abdominal CT, pelvic MRI and colonoscopy.*
*QOL evaluation (T0)*

**Neoadjuvant treatment:**

- **RT + Chemotherapy**
  - Oral capecitabine 1650 mg/m² for 5 days / 5 weeks.
  - Bolus 5-Fu 350 mg/m² + LV 20 mg/m² for 5 days on week 1 and 5.

**Radiotherapy (RT): 4500 cGy + 540 cGy 28 in 5 weeks.**

**Adjuvant treatment:**

- **Chemotherapy**
  - **ypT0-2/N0:** Bolus 5-Fu 370 mg/m² + LV 50 mg/m² weekly for 30 weeks.
  - **ypT3-4 ou N+:** Oxaliplatin 85mg/m² on days 1, 15 and 29; 5-Fu 500mg/m² + LV 20mg/m² on days 1, 8, 15, 22, 29 and 36 of each cycle. Total of 3 cycles or 24 weeks.

**Surgery**

**Rectal Resection**

- **Restaging with MRI, CTs and rectal endoscopy.**
- **QOL evaluation (T1).**
- **Pathological evaluation.**
- **QOL evaluation (T2).**

**QOL evaluation (T3).**

*Surgery 6-8 weeks after neoCRT completion*

INCAG1004

**Figure 1**
Figure 1 illustrates the study design. Clinical downstaging was the study primary endpoint and was defined as stage regression 6-8 weeks after neoCRT, using AJCC 7th edition (29).

EORTC’s QLQ C30 and CR38

- Quality of Life evaluation at five moment times

![Diagram showing the study timeline with events and time points: T0, T1, T2, T3, T4.]

*Wexner score evaluated at T4

Figure 2

EORTC QLQ C30 (20) and CR38 (21) were applied at five different treatment moments: before neoCRT (T0), 6-8 weeks after neoCRT (T1), 30 days after surgery (T2), after adjuvant chemotherapy (T3), and one year after the end of the treatment or stoma closure (T4) (Figure 2).
Figure 3

Figure 3 illustrate the study flow chart. Supplementary Table 2 reports the mean C30 and CR38 scores in all domains including the C30SumScore.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryTable1QOL.docx
- SupplementaryTable02.docx
- Graphic1.jpg